EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
news

Allergan eye drug fails to impress on safety, upping pressure ahead of key meeting

Allergan on Tuesday disclosed new safety results for an experimental eye drug, abicipar, but a modest improvement in a key inflammation rate failed to convince Wall ...
Continue Reading →
news

Dementia: Amyloid PET scans can improve diagnosis and care

PET scans that can detect changes in the brain relating to Alzheimer's disease could improve the diagnosis and medical care of people with dementia and similar sympt...
Continue Reading →
news

Early pancreatic cancer data give Clovis a new path in PARP market

Early Phase 2 data suggest Clovis Oncology's targeted cancer drug Rubraca may work as a maintenance therapy for certain pancreatic cancer patients, according to a st...
Continue Reading →
Asia Pacific

Astellas’ AML therapy bests chemo in Phase 3 study

In a Phase 3 trial, Astellas’ Xospata improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) compared to chemotherapy, according to ...
Continue Reading →
news

Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration...
Continue Reading →
Europe

Clinical trial finds therapy to be well-tolerated in patients with aggressive brain tumour

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tole...
Continue Reading →
news

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma

Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Toronto, Ontario, and Somerset, N.J. – April 1, 2019 – Triphase Acc...
Continue Reading →
news

FDA warns doctors, myeloma patients of doubled death risk from AbbVie, Roche’s Venclexta

Trial patients receiving benefit from Venclexta can continue taking the drug, the FDA said. (AbbVie) Earlier this month, the FDA halted enrollment in multiple my...
Continue Reading →
Europe

AZ’s Farxiga nabbed its Type 1 nod in EU. But after Zynquista’s rebuff, how will it fare at FDA?

AstraZeneca’s Farxiga just won European Commission approval in Type 1 diabetes, but a tough FDA review lies ahead. (AstraZeneca) AstraZeneca’s Farxiga just won E...
Continue Reading →
news

Parkinson’s: Study reveals how cancer drug reduces toxic protein in brain

Laboratory and animal studies have suggested that the leukemia drug nilotinib could alleviate symptoms of Parkinson's disease. Now, using early results from a clini...
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18